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The Role of Law in the Debate over 
Return of Research Results and 
Incidental Findings: The Challenge of 
Developing Law for Translational Science 
 
Susan M. Wolf* 
I. THE THREAT OF LAW 
The debate over return of individual results and incidental 
findings to human beings who participate in research or whose 
specimens and data are used is haunted by law. The 
recommendations that have emerged so far in this contentious 
debate typically refer in the United States to the framework set 
by the federal regulations on human subjects research, federal 
law and regulations on privacy, and the federal rules on the 
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certification of laboratories to offer test results for use in 
clinical care.1 Some commentators have ventured into state law 
on human subjects research, privacy, and ownership and 
control of specimens and data.2 But all of this gives little 
comfort. There is no law directly on point.3 The federal research 
regulations say nothing explicitly as yet about incidental 
findings or return of individual research results. The privacy 
regulations are equally silent. And the Centers for Medicare & 
Medicaid Services (CMS), which administers the key federal 
law on laboratory quality, has issued no official statement or 
rule.4 To date, no reported legal case has been discovered that 
addresses return of results or incidental findings in the domain 
of research. 
Some commentators have taken this as occasion to worry 
                                                          
 1. See, e.g., Susan M. Wolf et al., Managing Incidental Findings in 
Human Subjects Research: Analysis and Recommendations, 36 J.L. MED. & 
ETHICS 219 (2008); Richard R. Fabsitz et al., Ethical and Practical Guidelines 
for Reporting Genetic Research Results to Study Participants: Updated 
Guidelines from an NHLBI Working Group, 3 CIRCULATION: CARDIOVASCULAR 
GENETICS 574-80 (2010); Susan M. Wolf et al., Managing Research Results 
and Incidental Findings in Genomic Research Involving Biobanks & Archived 
Datasets, 14 GENETICS MED. 361 (2012). 
 2. See, e.g., Leili Fatehi & Ralph Hall, Enforcing the Rights of Human 
Sources to Informed Consent and Disclosures of Incidental Findings from 
Biobanks and Researchers: State Mechanisms in Light of Broad Regulatory 
Failure, 13 MINN. J. L. SCI. & TECH. 575 (2012). 
 3. Cf. Ellen Wright Clayton & Amy L. McGuire, The Legal Risks of 
Returning Results of Genomic Research, 14 GENETICS MED. 473, 475 (2012) 
(“There is no legislation requiring disclosure of research results…. [and] no 
lawsuits have found investigators liable for failing to provide such 
information….”). For additional legal analyses prior to this symposium that 
address return of results and incidental findings under U.S. law, see, e.g., 
Susan M. Wolf, Incidental Findings in Neuroscience Research: A Fundamental 
Challenge to the Structure of Bioethics and Health Law, in THE OXFORD 
HANDBOOK OF NEUROETHICS 623-34 (Judy Illes & Barbara J. Sahakian eds.,  
2011); Henry T. Greely, The Uneasy Ethical and Legal Underpinnings of 
Large-Scale Genomic Biobanks, 8 ANN. REV. GENOMICS & HUM. GENETICS 343 
(2007); Alan C. Milstein, Research Malpractice and the Issue of Incidental 
Findings, 36 J.L. MED. & ETHICS 356 (2008); Anne Marie Tassé, The Return of 
Results of Deceased Research Participants, 39 J.L. MED. & ETHICS 621 (2011); 
Stacey A. Tovino, Incidental Findings: A Common Law Approach, 15 
ACCOUNTABILITY RES.: POLICIES & QUALITY ASSURANCE 242 (2008); Susan M. 
Wolf, Jordan Paradise & Charlisse Caga-anan, The Law of Incidental 
Findings in Human Subjects Research: Establishing Researchers’ Duties, 36 
J.L. MED. & ETHICS 361 (2008). 
 4. Some CMS officials have graciously presented at meetings and 
conferences on this issue, but such presentations do not have the status and 
force of a rule. 
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about lurking legal liability. It appears to be little reassurance 
that no court, to my knowledge, has yet found anyone liable for 
mishandling return of results or incidental findings in the 
context of human subjects research. Indeed, no one has 
apparently even been sued. Yet already, we see views 
expressed that researchers must navigate between legal 
threats on both sides – liability for failure to return findings on 
one side, and liability for wrongly returning on the other. Faced 
with the specter of this Scylla and Charybdis, it is small 
wonder that researchers are already showing anxiety. 
This symposium can play an important role, offering eight 
articles on different aspects of law, ethics, and practice. These 
articles grew out of a two-year project funded by the National 
Human Genome Research Institute (NHGRI) at the National 
Institutes of Health (NIH).5 This project was the second in 
what has become a trajectory of research efforts on return of 
results and incidental findings at the University of Minnesota’s 
Consortium on Law and Values in Health, Environment & the 
Life Sciences.6 Our first grant, the first NIH-funded grant to 
our knowledge whose focus was on this return of results 
question, analyzed the approach to incidental findings in 
imaging and genetics research. Our second grant—which 
supported development of this symposium in the Minnesota 
Journal of Law, Science & Technology (MJLST)—has analyzed 
how to handle incidental findings and individual research 
results in large-scale genomic research involving biobanks and 
archived data sets. Our third grant, awarded last year, is 
concentrating on the cutting-edge question of return of findings 
                                                          
 5. NIH, NHGRI grant #2-R01-HG003178 on “Managing Incidental 
Findings and Research Results in Genomic Biobanks & Archives” (Wolf, 
Principal Investigator; Kahn, Lawrenz & Van Ness, Co-Investigators) (2009-
11). 
 6. That trajectory includes NIH, NHGRI grant #2-R01-HG003178 on 
“Managing Incidental Findings in Human Subjects Research” (Wolf, Principal 
Investigator; Kahn, Lawrenz, Nelson & Paradise, Co-Investigators) (2005-07); 
NIH, NHGRI grant #2-R01-HG003178 on “Managing Incidental Findings and 
Research Results in Genomic Biobanks & Archives” (Wolf, Principal 
Investigator; Kahn, Lawrenz & Van Ness, Co-Investigators) (2009-11); and 
NIH, National Cancer Institute (NCI) & NHGRI grant #1-R01-CA154517 on 
“Disclosing Genomic Incidental Findings in a Cancer Biobank: An ELSI 
Experiment” (Petersen, Koenig & Wolf, Principal Investigators) (2011-16). A 
fourth grant recently awarded is a Robert Wood Johnson Foundation 
Investigator Award in Health Policy Research on “Translating Research into 
Health Benefits: Returning Research Results & Incidental Findings” (Wolf, 
Principal Investigator) (2012-14). 
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This symposium is our second published collection of 
articles funded by the NIH grant on return of incidental 
findings and research results in large-scale genomic research 
involving biobanks and archived data sets. That project 
produced a symposium already published in the April 2012 
issue of Genetics in Medicine (GIM). The GIM symposium 
featured a 26-author consensus recommendations article that is 
discussed by many of the articles in this issue of MJLST.7 
It is fitting that MJLST devote an issue to this problem. 
Concern over law and liability is beginning to loom large in the 
debate over return of research results and incidental findings. 
Like many cutting-edge issues in biomedicine, resolution of this 
one could go seriously astray if anxieties about law and liability 
become determinative. This is a familiar dynamic – an issue 
emerges in biomedicine; the law is unclear or in transition; 
faced with uncertainty, fear of liability and regulatory penalties 
begins to erupt; mythology about what law requires gains a 
foothold; and resolutions that would be better guided by ethics, 
evidence, and established principles of practice, now have to 
contend with overblown fears of law. There is a classic 
literature on this dynamic.8 
Excessive concern with law, especially early in the 
development of sound practice and ethical consensus on good 
approaches, can stunt the development of appropriate and 
effective non-legal norms. Though law and ethics are 
sometimes confused, they are distinct. Again, a classic 
literature reminds us that law and ethics are indeed different; 
in some domains they actually conflict.9 On emerging 
                                                          
 7. Wolf et al., Managing Research Results, supra note 1. 
 8. See, e.g., Emily R. Carrier et al., Physicians’ Fears of Malpractice 
Lawsuits Are Not Assuaged by Tort Reforms, 29 HEALTH AFF. 1585 (2010); 
Sandra H. Johnson, The Social, Professional, and Legal Framework for the 
Problem of Pain Management in Emergency Medicine, 33 J.L. MED. & ETHICS 
741 (2005); S. Van McCrary et al., Treatment Decisions for Terminally Ill 
Patients: Physicians’ Legal Defensiveness and Knowledge of Medical Law, 20 
L. MED. & HEALTH CARE 364 (1992); Alan Meisel, The Legal Consensus About 
Forgoing Life-Sustaining Treatment: Its Status and Prospects, 2 KENNEDY 
INST. ETHICS J. 309 (1993); Alan Meisel et al., Seven Legal Barriers to End-of-
Life Care: Myths, Realities, and Grains of Truth, 284 JAMA 2495 (2000); 
Mildred Z. Solomon et al., Decisions Near the End of Life: Professional Views 
on Life-Sustaining Treatments, 83 AM. J. PUB. HEALTH 14-23 (1993); David M. 
Studdert et al., Medical Malpractice, 350 N. ENG. J. MED. 283 (2004). 
 9. See, e.g., GEORGE J. ANNAS, STANDARDS OF CARE: THE LAW OF 
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biomedical questions, it can be highly adaptive for ethics and 
biomedical practice (whether clinical practice or research 
practice) to take the lead, exploring and testing potential 
approaches. Clarity in the domain of ethics and practice can 
support the development of good law. Indeed, sound law in the 
world of biomedicine generally supports ethical and competent 
practice. In fact, conclusions about what is ethically correct for 
the research community and individual researchers in dealing 
with return of results and incidental findings is likely to 
predate the development of law on these issues. 
The goal of this article is to address emerging legal 
concerns in the debate over return of results and incidental 
findings, clarify what is not at issue, and then make clear the 
true nature of the challenge for law. The ultimate purpose of 
this analysis is not to discourage work on law, which is surely 
needed, but to optimize its contribution to a sound process of 
resolution. To shape ethics and practice around premature 
conclusions of legal threat would be to thwart an extremely 
important debate in research ethics and practice. Much about 
law is simply not yet clear in this debate. And this article 
suggests that there is a reason for this lack of clarity: neither 
the law of research nor the law of clinical care is fully adequate 
to govern what is in essence a problem about the translational 
process of moving research-derived information into the domain 
of clinical care. We need to develop law that is appropriate for 
this translational science process. This is a substantial 
challenge. We need to seize the opportunity afforded by these 
early days of debate to shape and develop law in a way that will 
support sound and sustainable answers. 
After all, where law works well in biomedicine, it is 
because law supports practices that make sense medically, 
scientifically, and ethically. Where law threatens to derail 
sound research or clinical practice or the translational process 
between them, it offers answers that are difficult to defend and 
sustain. Law should ultimately support sound resolution of the 
issues surrounding return of results and incidental findings. 
                                                          
AMERICAN BIOETHICS (1993); Alexander M. Capron & Vicki Michel, Law and 
Bioethics, 27 LOY. L.A. L. REV. 25 (1993); Richard Delgado & P. McAllen, The 
Moralist as Expert Witness, 62 B.U. L. REV. 869 (1982); Carl E. Schneider, 
Bioethics in the Language of the Law, 24(4) HASTINGS CENT. REP. 16 (1994); 
Susan M. Wolf, Law & Bioethics: From Values to Violence, 32 J.L. MED. & 
ETHICS 293 (2004); Susan M. Wolf, Ethics Committees in the Courts, 16(3) 
HASTINGS CENT. REP. 12 (1986). 
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II. EMERGING CONCERNS ABOUT LAW 
As work on the law of returning results and incidental 
findings gets under way, a few concerns about law are 
emerging that warrant careful consideration. More work over 
time will be needed on law, to make sure law supports sound 
resolution of the issues raised by return of results and 
incidental findings. At this early point, one of the biggest 
dangers is that fear of law will derail good progress in the 
return of results debate. Below are three concerns that have 
been voiced as reasons to avoid or minimize return of results 
and incidental findings. However, careful examination suggests 
that none of these is a compelling reason. There may be other 
important reasons to limit return, but these broad legal 
concerns should not shut down exploration of return of results 
and incidental findings. 
A. THE CONCERN THAT ETHICS RECOMMENDATIONS  
WILL BE MISTAKEN FOR LAW 
Since at least 1999, over a dozen years ago, we have seen 
published ethics recommendations on return of results and 
incidental findings in research. In 1999, the National Bioethics 
Advisory Commission (NBAC) advised returning results only if 
“scientifically valid and confirmed,” “the findings have 
significant implications for the subjects’ health concerns,” and 
“a course of action to ameliorate or treat these concerns is 
readily available.”10 In 2001, a project sponsored by the Centers 
for Disease Control (CDC) recommended criteria for returning 
results in population-based genetic research: “When the risks 
identified in the study are both valid and associated with a 
proven intervention for risk reduction, disclosure may be 
appropriate.”11 In 2004 and 2010, Working Groups sponsored 
by the National Heart, Lung, and Blood Institute (NHLBI) at 
NIH issued consensus recommendations; the latter specified 
when results should be offered and when they may be offered to 
research participants.12 In 2005, a Committee of the National 
                                                          
 10. NATIONAL BIOETHICS ADVISORY COMMISSION (NBAC), 1 RESEARCH 
INVOLVING HUMAN BIOLOGICAL MATERIALS: ETHICAL ISSUES AND POLICY 
GUIDANCE 72 (1999). 
 11. Laura M. Beskow et al., Informed Consent for Population-Based 
Research Involving Genetics, 286 JAMA 2315, 2320 (2001). 
 12. Ebony B. Bookman et al., Reporting Genetic Results in Research 
Studies: Summary and Recommendations of an NHLBI Working Group, 140A 
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Research Council and Institute of Medicine published 
consensus recommendations on return of research results in 
human embryonic stem cell research, stating that the duty to 
report “depends in large part on the reliability of the findings 
and the significance of the information to human health.”13 In 
2008, the investigators and Working Group members in our 
first project on return of incidental findings published a 21-
author consensus recommendations article specifying when 
incidental findings should be returned, may be returned, and 
should not be returned.14 Also in 2008, Caulfield and colleagues 
published recommendations on return of results in whole-
genome research.15 And earlier this year, we published our 
second consensus recommendations paper on return of results 
and incidental findings in large-scale genomic research 
involving biobanks and archived data sets.16 
All of these papers present ethics recommendations. And to 
date, not a single one of them appears to have been cited in any 
legal decision or used to impose liability. There is a very good 
reason for this: ethics is not the same as law. What is 
recommended in these papers are general principles, such as 
differentiate “should return” from “may return,” plan for and be 
careful about the return process, limit return to findings that 
are well-understood and actionable, and seek consent from 
research participants before returning information. It is widely 
recognized that translating such general principles into action 
will require a great deal more work. Even devising the roster of 
results that are indeed established and actionable will be a 
complex and collaborative process. Research is under way to 
support specification of the general ethics principles articulated 
to date. Indeed, in our latest recommendations paper, we 
separated the process of articulating general criteria for return 
from the process of analyzing particular findings to decide if 
they should be returned.17 
                                                          
AM. J. HUM. GENETICS 1033 (2006); Fabsitz et al., supra note 1. 
 13. NATIONAL RESEARCH COUNCIL AND INSTITUTE OF MEDICINE 
COMMITTEE ON GUIDELINES FOR HUMAN EMBRYONIC STEM CELL RESEARCH, 
GUIDELINES FOR HUMAN EMBRYONIC STEM CELL RESEARCH 89-90 (2005). 
 14. Susan M. Wolf et al., Managing Incidental Findings in Human 
Subjects Research: Analysis and Recommendations, 36 J.L. MED. & ETHICS 
219 (2008). 
 15. Timothy Caulfield et al., Research Ethics Recommendations for Whole-
Genome Research: Consensus Statement, 6(3) PLOS BIOL. e73 (2008). 
 16. Wolf et al., Managing Research Results, supra note 1. 
 17. Id., at 374-75. 
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We would all be kidding ourselves to believe that we had 
already generated such consensus across the research 
community about return of results and incidental findings and 
such specificity about what return should look like that courts 
would find an established standard of care. The reality is that 
debate, research, and specification are very obviously works in 
progress. NIH is playing a crucial role in funding the 
significant quantity of research still needed to form an evidence 
base for research standards, and linking investigators in a 
Return of Results Consortium to advance progress.18 I have 
written elsewhere that agreeing on well-supported standards 
for the research community will probably require years of 
work.19 
Another reason to look skeptically on claims that our 
current ethics recommendations will generate legal liability is 
that the ethics literature to date acknowledges that research 
studies vary significantly, as do biobanks and other research 
resources. It is highly doubtful that a single policy or standard 
will suffice for all. Indeed, our project’s recent ethics 
recommendations for biobank research systems recognized 
variation in how such systems are structured, whether re-
identification of individual participants is possible, and 
whether return involves retrofitting a preexisting biobank or 
prospectively designing a new one.20 Underscoring this, an 
article published in our project’s Special Issue of GIM examined 
the approach to return of results across five biobanks that were 
all members of the NIH-funded eMERGE Network; the article 
documented a wide range of approaches to return of results, 
even though all five sites were considering the 
recommendations of a joint Return of Results Oversight 
Committee.21 
It is true that when consensus recommendations to date 
consider return of results, they look at a number of informative 
                                                          
 18. See Jeannine Mjoseth, NHGRI Funds Return of Results Studies, 
Forms Expert Consortium, http://www.genome.gov/27545526 (last visited May 
8, 2012). 
 19. Susan M. Wolf, The Past, Present, and Future of the Debate over 
Return of Research Results & Incidental Findings, 14 GENETICS MED. 355 
(2012). 
 20. See Wolf et al., Managing Research Results, supra note 1. 
 21. Stephanie M. Fullerton et al., Return of Individual Research Results 
from Genome-Wide Association Studies: Experience of the Electronic Medical 
Records and Genomics (eMERGE) Network, 14 GENETICS MED. 424 (2012). 
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sources, including of course the regulations on human subjects 
research and sometimes statutes such as the Clinical 
Laboratory Improvement Amendments (CLIA) and the Health 
Insurance Portability and Accountability Act (HIPAA). Ethics 
groups examine these sources to try to inform and reconcile 
their recommendations with already-existing rules. That said, 
there is no guarantee that ethics groups will find the current 
law adequate. There are many examples in the history of 
bioethics and medical ethics of ethics authorities and scholars 
as well as practicing clinicians finding the law wanting and 
even in conflict with sound ethics.22 Because the regulations on 
human subjects research, CLIA, and HIPAA were devised with 
no attention to the problem of return of results and incidental 
findings, we should not be surprised if sustained ethics analysis 
finds these legal sources wanting and in need of development or 
amendment to adequately address these issues. 
B. THE CONCERN THAT RETURN OF RESULTS &  
INCIDENTAL FINDINGS MISTAKES RESEARCH  
FOR CLINICAL CARE 
The claim that return of research results and incidental 
findings mistakes research for clinical care restates the 
question at the heart of the return of results debate, rather 
than providing an answer. The question of whether to return 
results and incidental findings from research is a challenging 
one precisely because the context is research and not clinical 
care. Research is classically defined as the search for 
generalizable knowledge.23 Traditionally researchers have 
recognized no responsibility to communicate clinically 
important information about individuals, with limited 
exceptions.24 Both law and ethics have conceived of the 
research and clinical spheres as generally quite distinct. The 
researcher has been seen as owing limited duties to the 
individual research participants, in contrast to the clinician, 
                                                          
 22. For examples and an exploration of the relationship of law and 
bioethics, see Susan M. Wolf, Law & Bioethics: From Values to Violence, 32 
J.L. MED. & ETHICS 293 (2004). 
 23. This is based on the Common Rule definition of “research” as “a 
systematic investigation, including research development, testing and 
evaluation, designed to develop or contribute to generalizable knowledge.” 45 
C.F.R. § 46.102 (d) (2011). 
 24. Exceptions would include duties to report “significant new findings 
developed during the course of the research which may relate to the subject’s 
willingness to continue participation” (45 C.F.R. § 46.116 (b) (5) (2011)). 
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who undertakes a broad duty of care toward the individual 
patient. 
The discovery that research routinely and predictably 
generates information of clinical significance to individual 
participants, whether in the form of individual research results 
or incidental findings, has challenged this traditional 
dichotomy between research and clinical care.25 When some 
findings have urgent clinical significance (such as 
pharmacogenetic findings revealing that the individual may 
have a catastrophic reaction to a commonly used drug), the 
tradition of researcher silence becomes more difficult to defend. 
Indeed, it has become hard to find participants in the return of 
results debate who maintain that no individual results or 
findings should ever be returned, no matter how clinically 
urgent the information. Imaging researchers long ago accepted 
responsibility for reporting findings of serious clinical 
significance.26 Genetic and genomic researchers have come 
more slowly to this acceptance of responsibility, but now are 
hard at work fleshing out what it should mean in research 
practice. 
The literature increasingly offers ethical theories and 
argument about the grounding and scope of the responsibility. 
But for our purposes here, the key insight is that the research 
context is precisely what necessitates this philosophical work. 
Were we instead talking about the clinical context, no complex 
argument would be needed to support the notion that a 
clinician treating malady X who stumbles upon additional 
malady Y has a duty to convey that information to the patient, 
so that the patient can decide whether and how to address the 
newly discovered problem. 
The challenge of the return of results debate is that it 
forces us to rethink the traditional wall between research and 
clinical care, by raising the question of whether researchers 
have some informational duties to convey findings of high 
clinical significance to the individual participant. This is a deep 
challenge to the traditional architecture of both health law and 
bioethics, which have largely accepted and built upon a 
dichotomy between the two spheres. To restate the difference 
                                                          
 25. See Susan M. Wolf, Incidental Findings in Neuroscience Research, 
supra note 3. 
 26. See Wolf et al., Managing Incidental Findings, supra note 1. 
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between research and clinical care is no answer to what to do in 
the face of this challenge; it merely recapitulates the question. 
Just as it is increasingly difficult to find commentators who 
argue for no return, no matter how urgent the information, it is 
also increasingly difficult to find commentators who argue for 
conveying all information derived in the research sphere, at 
least at this juncture. Too much of that information still 
remains uncertain and even mistaken, to dump it all on 
research participants. Thus, the scope of the responsibility to 
return is at this point limited. This accounts for the effort in 
publication after publication to articulate the criteria that 
should be met before return is undertaken. 
There is no denying that allowing the traditional wall 
between research and clinical care to give way is unsettling.  
The wall is starting to resemble something more like a 
membrane allowing some kinds of information through. We 
remain in the early days of the research required to figure out 
what to return and how—the appropriate functioning of this 
permeable membrane. But it is no accident that this conceptual 
shift is happening now. The rise of a translational concept of 
genetics and genomics has brought into focus the precise 
process by which research moves into clinical practice. 
Increasingly, the goal of research is to move information and 
interventions into clinical use. And not just for populations—
individualized or personalized medicine embraces the reality of 
individual genetic and genomic difference. When translational 
science is combined with personalized medicine, it is inevitable 
that researchers have to confront the question of how and when 
research information should be offered to individuals because of 
that information’s potential clinical significance. Instead of two 
domains separated by a wall, research and clinical care have 
become part of a spectrum that moves research insights into 
clinical use. 
In the face of this, to say that the return of results 
mistakes research for clinical care is a throwback to a time 
before we embraced that continuum, with all of its challenges. 
There is no going back to the two-world vision. What has 
emerged is more complex and continuous.  
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C. THE CONCERN THAT RESEARCH RESULTS &  
INCIDENTAL FINDINGS CANNOT MEET STANDARDS  
FOR RESPONSIBLE RETURN 
There is wide agreement that returning findings to 
research participants calls for confidence that the test 
performed and information derived have acceptable accuracy, 
the clinical implications are understood, and the sample and 
data in question indeed belong to this participant. Thus we see 
a near-universal demand for analytic validity as a precondition 
for informational return.27 A further recommendation has been 
that an individual research result or incidental finding has 
“established” risk or meaning.28 There is debate about how 
established the risk or meaning should be to allow return, and 
whether to offer research participants not only findings, but 
also information on how well understood and established the 
associated risk or meaning is. Yet another recommendation on 
the protective standards that should condition return is the 
frequently stated—but still somewhat controversial—
requirement that any findings to be returned are generated 
and/or confirmed in a CLIA-certified laboratory.29 
All of these issues are aspects of a single question: What 
standards should apply to govern the quality of information 
that is offered to research participants? In addressing this 
question, it is important to recognize that notifying research 
participants of an incidental finding or individual research 
result of concern is typically not suggested as a substitute for 
clinical diagnosis and care. In imaging research, for example, 
research scans may not be of clinical grade and optimized for 
clinical diagnosis. Thus, what research will often generate is 
findings and results of potential clinical concern. So the 
question is what level of confidence about the finding and its 
clinical implications is necessary before sharing this 
                                                          
 27. See, e.g., Fabsitz et al., supra note 1, at 575, 578; Wolf et al., 
Managing Return of Results, supra note 1, at 378. In genomic testing, 
“analytic validity” refers to “[h]ow accurately and reliably the test measures 
the genotype of interest.” “Clinical validity” refers to “[h]ow consistently and 
accurately the test detects or predicts the…outcomes of interest.” Centers for 
Disease Control and Prevention, Genomic Testing: ACCE Model Process for 
Evaluating Genetic Tests, available at http://www.cdc.gov/genomics/gtesting/  
ACCE/index.htm (last visited May 3, 2012). 
 28. See, e.g., Fabsitz et al., supra note 1, at 575. 
 29. On the CLIA controversy, see, e.g., Fabsitz et al., supra note 1, at 576-
77; Wolf et al., Managing Return of Results, supra note 1, at 371. 
001 WOLF_PROOF - SK.DOCX (DO NOT DELETE) 7/5/2012  1:07 PM 
2012] ROLE OF LAW 447 
information in order to trigger the research participant’s 
pursuit of definitive clinical diagnosis and care. 
To simply say that the standards of clinical testing and 
diagnosis should apply wholesale is to avoid what is at the 
heart of the return of results and incidental findings debate – a 
translational question30 of what research information is 
appropriate for return. This is a complex question, whose 
answer may vary depending on a range of variables, including 
the nature of the research participant population in question, 
whether the research participants are healthy volunteers or 
individuals affected by a condition they are trying to cope with 
and understand, and whether clinical work-up is readily 
available once the research-generated information is offered to 
trigger that clinical consideration. Returning results and 
incidental findings meeting all of the quality standards for 
communication in a clinical setting (including findings that are 
already routinely communicated in clinical settings) may turn 
out to be the easy case. More challenging will be consideration 
of other cases, such as cases in which a novel genetic or 
genomic abnormality is found with too little literature to say its 
meaning is “established,” but raising such concern among 
genetics professionals that they consider sharing the 
information to contribute to diagnostic efforts that have thus 
far been unavailing. This is a scenario that would require 
careful and detailed consideration, but is already of concern to 
researchers. 
II. THE REAL CHALLENGE: DEVISING 
TRANSLATIONAL ETHICS, PRACTICE, & LAW 
Making progress in the debate over return of research 
results and incidental findings requires recognizing that the 
debate is fundamentally about the translational process. 
Return of information generated in the process of conducting 
research, because of the potential clinical importance of that 
information, is a practice that occupies the space between 
research and clinical care. It does not fit neatly into the 
preexisting ethics or law of either research or clinical care. It 
                                                          
 30. On translational genomics and translational science more generally, 
see, e.g., Muin J. Khoury et al., The Continuum of Translation Research in 
Genomic Medicine: How Can We Accelerate the Appropriate Integration of 
Human Genome Discoveries into Health Care and Disease Prevention?, 9 
GENETICS MED. 665 (2007); Elias A. Zerhouni, Translational and Clinical 
Science—Time for a New Vision, 353 N. ENG. J. MED. 1621 (2005). 
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lies in the domain between them. There is no escaping that this 
translational practice is calling for the development of new 
ethical approaches and insights. It similarly calls for the 
development of legal standards that fully consider the 
translational character and complexities of this practice. 
The traditional ethics and law of research (on the one 
hand) and clinical care (on the other) are surely relevant to 
developing this translational ethics and law. But they were not 
developed with careful attention to this problem and are not 
adequate to its resolution. The emergence of translational 
genomics requires an ethics that is evolving. And it requires 
the development of law that addresses the complexities of 
translational practices soundly and sustainably. We do not yet 
have such law in place. Developing translational law lies 
largely ahead of us.31 This symposium aims to contribute to 
that effort. 
 
                                                          
 31. For beginning efforts, see, e.g., Gary E. Marchant, Personalized 
Medicine and the Law, ARIZONA ATTORNEY, Oct. 2007, at 12, available at 
http://papers.ssrn.com/sol3/papers.cfm?abstract_id=1469686 (last visited May 
8, 2012); Michael Tomasson, Legal, Ethical, and Conceptual Bottlenecks to the 
Development of Useful Genomic Tests, 18 ANN. HEALTH L. 231 (2009). 
